Germany· DE-A57-0895d63595bde5a9
Tenofoviralafenamid Devatis
A tenofovir alafenamide product containing tenofovir alafenamide, registered in Germany by Devatis Gmbh. The same ATC class is registered in 14 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Tenofovir alafenamide is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AF13 (tenofovir alafenamide), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 8 of them publish a price we can compare per daily dose
Tenofovir alafenamide · ATC J05AF13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tenofovir alafenamide costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tenofovir alafenamide · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.29
- IT Italy$18.37
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Tenofovir Alafenamide
- Manufacturer
- Devatis Gmbh
- Country
- Germany (DE)
- ATC code
- J05AF13
- ATC class
- Tenofovir alafenamide
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J05AF13
Tenofovir alafenamide, as other registers publish it.
- NetherlandsTenofoviralafenamide Devatis 25 mg, filmomhulde tablettenDevatis GmbH
- FinlandVemlidyGilead Sciences Ireland UC
- NorwayVemlidyGilead Sciences Ireland UC
- FinlandVemlidyOrifarm Oy
- FinlandVemlidyAbacus Medicine A/S
- FinlandVemlidy2care4 ApS
- DenmarkVemlidyGilead Sciences Ireland UC
- FinlandVemlidyParanova Oy
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/46064695-fabb-450e-8452-4dd61b113854 GET /v1/drugs/46064695-fabb-450e-8452-4dd61b113854?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Tenofovir Alafenamide",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about tenofovir alafenamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.